Sanguinarine Suppresses Prostate Tumor Growth and Inhibits Survivin Expression
Authors:
Open Access
- 1 March 2010
- journal article
- research article
- Published by SAGE Publications in Genes & Cancer
- Vol. 1 (3) , 283-292
Abstract
Prostate cancer is a frequently occurring disease and is the second leading cause of cancer-related deaths of men in the United States. Current treatments have proved inadequate in curing or controlling prostate cancer, and a search for agents for the management of this disease is urgently needed. Survivin plays an important role in both progression of castration-resistant prostate cancer and resistance to chemotherapy. Altered expression of survivin in prostate cancer cells is associated with cancer progression, drug/radiation resistance, poor prognosis, and short patient survival. In the present study, the authors performed a cell-based rapid screen of the Prestwick Chemical Library consisting of 1120 Food and Drug Administration–approved compounds with known safety and bioavailability in humans to identify potential inhibitors of survivin and anticancer agents for prostate cancer. Sanguinarine, a benzophenanthridine alkaloid derived primarily from the bloodroot plant, was identified as a novel inhibitor of survivin that selectively kills prostate cancer cells over “normal” prostate epithelial cells. The authors found that sanguinarine inhibits survivin protein expression through protein degradation via the ubiquitin-proteasome system. Sanguinarine induces apoptosis and inhibits growth of human prostate cancer cells and in vivo tumor formation. Administration of sanguinarine, beginning 3 days after ectopic implantation of DU145 human prostate cancer cells, reduces both tumor weight and volume. In addition, sanguinarine sensitized paclitaxel-mediated growth inhibition and apoptosis, offering a potential therapeutic strategy for overcoming taxol resistance. These results suggest that sanguinarine may be developed as an agent either alone or in combination with taxol for treatment of prostate cancer overexpressing survivin.Keywords
This publication has 48 references indexed in Scilit:
- Selenium inhibition of survivin expression by preventing Sp1 binding to its promoterMolecular Cancer Therapeutics, 2007
- YM155, a Novel Small-Molecule Survivin Suppressant, Induces Regression of Established Human Hormone-Refractory Prostate Tumor XenograftsCancer Research, 2007
- Survivin study: An update of “What is the next wave?”Journal of Cellular Physiology, 2006
- Rational design of shepherdin, a novel anticancer agentCancer Cell, 2005
- Survivin study: What is the next wave?Journal of Cellular Physiology, 2003
- Triplex-forming oligodeoxynucleotides targeting survivin inhibit proliferation and induce apoptosis of human lung carcinoma cellsCancer Gene Therapy, 2003
- Regulation of apoptosis at cell division by p34 cdc2 phosphorylation of survivinProceedings of the National Academy of Sciences, 2000
- A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy.2000
- The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression.1999
- THE UBIQUITIN SYSTEMAnnual Review of Biochemistry, 1998